CMS plans a voluntary five-year trial allowing state Medicaid and Medicare Part D plans to cover GLP-1 weight management drugs, including Ozempic and Wegovy, starting in 2026-27 amid pricing and coverage challenges.

The Trump administration proposes a Medicare and Medicaid pilot program for covering GLP-1 weight loss drugs, marking a key shift in healthcare policy and potential budget impacts.

Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.